AORT vs. ATRC, EMBC, ATRI, SILK, MDXG, KIDS, FNA, SIBN, OFIX, and IRMD
Should you be buying Artivion stock or one of its competitors? The main competitors of Artivion include AtriCure (ATRC), Embecta (EMBC), Atrion (ATRI), Silk Road Medical (SILK), MiMedx Group (MDXG), OrthoPediatrics (KIDS), Paragon 28 (FNA), SI-BONE (SIBN), Orthofix Medical (OFIX), and Iradimed (IRMD). These companies are all part of the "surgical & medical instruments" industry.
AtriCure (NASDAQ:ATRC) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings.
AtriCure has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.
In the previous week, AtriCure had 4 more articles in the media than Artivion. MarketBeat recorded 6 mentions for AtriCure and 2 mentions for Artivion. AtriCure's average media sentiment score of 1.14 beat Artivion's score of 0.47 indicating that Artivion is being referred to more favorably in the news media.
AtriCure presently has a consensus price target of $49.78, suggesting a potential upside of 115.12%. Artivion has a consensus price target of $27.50, suggesting a potential upside of 12.29%. Given Artivion's higher probable upside, research analysts clearly believe AtriCure is more favorable than Artivion.
99.1% of AtriCure shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 3.2% of AtriCure shares are owned by insiders. Comparatively, 8.1% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
AtriCure received 533 more outperform votes than Artivion when rated by MarketBeat users. However, 70.00% of users gave Artivion an outperform vote while only 68.98% of users gave AtriCure an outperform vote.
Artivion has a net margin of -2.61% compared to Artivion's net margin of -8.98%. AtriCure's return on equity of 3.64% beat Artivion's return on equity.
AtriCure has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.
Summary
AtriCure beats Artivion on 9 of the 17 factors compared between the two stocks.
Get Artivion News Delivered to You Automatically
Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artivion Competitors List
Related Companies and Tools
